Abstract:Background Transcatheter aortic valve replacement is a treatment option for symptomatic patients with severe aortic stenosis who are candidates for a bioprosthesis across the entire spectrum of risk. TAVR carries a risk for thrombotic and bleeding events, underscoring the importance of defining the optimal adjuvant antithrombotic regimen. Antithrombotic consideration is complicated by the fact that many patients undergoing TAVR are generally elderly with multiple comorbidities, including conditions that may require long-term oral anticoagulation such as atrial fibrillation. The optimal antithrombotic regimen for patients with AF undergoing TAVR is currently unknown. The objective of this meta-analysis is to add knowledge to existing data involving the use of direct oral anticoagulant in patients with pre-existing atrial fibrillation undergoing TAVI and to explore the safety and efficacy of DOACs compared with VKA in this population Methods A systematic search for randomized controlled trials which compare direct oral anticoagulant and vitamin K antagonist was done using PubMed, Cochrane, MEDLINE and Clinicaltrials.gov. Studies which were done in the last five years (January 2016-October 2021) and those that involved human subjects were included in the study. Search terms include "Direct Oral Anticoagulant", "Vitamin K Antagonist", "TAVR", "atrial fibrillation", "DOAC" AND "TAVI" OR "VKA" AND "TAVI" AND "atrial fibrillation" AND "randomized controlled trial". Results Five retrospective observational studies and two RCTs (3,998) were included in this meta-analysis comparing direct oral anticoagulant vs vitamin K antagonist in patients with known atrial fibrillation post TAVI. Dabigatran, Rivaroxaban, Apixaban, and Edoxaban were used in these different studies. Among patients with concomitant indication of oral anticoagulant like atrial fibrillation, there is no significant difference between direct oral anticoagulant and vitamin K antagonist in terms of outcomes on all-cause mortality, major and/or life threatening bleeding and stroke as shown in these values, (OR 1.05, 95% CI: 0.89–1.25, P=0.57, I2=39%), (OR=1.04, 95% CI: 0.85–1.27, P=0.70, I2=45%) and (OR=1.10, 95% CI: 0.80–1.51, p=0.56, I2=0%), respectively. When only the two RCTs are compared, still there is no significant difference on the outcomes mentioned above between direct oral anticoagulant and vitamin K antagonist based on these values (OR=1.07, 95% CI: 0.85–1.36, P=0.57, I2=0%), (OR=1.15, 95% CI: 0.59–2.24, P=0.68, I2=66%) and (OR=0.99, 95% CI: 0.65–1.49, p=0.95, I2=39%), respectively. Conclusion Use of direct oral anticoagulant was non inferior with vitamin K antagonist in terms of outcomes on all-cause mortality, major and/or life threatening bleeding and stroke. Direct oral anticoagulant is easier to use with its known safety profile, hence, it is a plausible alternative to warfarin in this population in patients with known atrial fibrillation post TAVR. Funding Acknowledgement Type of funding sources: Private hospital(s). Main funding source(s): St. Luke's Medical Center Taguig City

[Direct Oral Anticoagulant Edoxaban in Patients with Non-Valvular Atrial Fibrillation: Results of Direct Comparison with Warfarin]

Comparison of transesophageal echocardiography findings after different anticoagulation strategies in patients with atrial fibrillation: a systematic review and meta-analysis

Direct Acting Oral Anticoagulant vs. Warfarin in the Prevention of Thromboembolism in Patients With Non-valvular Atrial Fibrillation With Valvular Heart Disease—A Systematic Review and Meta-Analysis

Application of the Win Ratio Method in the ENGAGE AF-TIMI 48 Trial Comparing Edoxaban With Warfarin in Patients With Atrial Fibrillation

Comparison of the Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

Comparison of Effectiveness and Safety of Direct-Acting Oral Anticoagulants and Vitamin K Agonists in Patients With Atrial Fibrillation and End-Stage Kidney Disease: A Systematic Review and Meta-Analysis

Clinical trial evaluation: the EDOSURE clinical trial program

Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure

Comparing Efficacy and Safety Between Patients With Atrial Fibrillation Taking Direct Oral Anticoagulants or Warfarin After Direct Oral Anticoagulant Failure

Anticoagulation in atrial fibrillation and end-stage kidney disease on hemodialysis: a meta-analysis of randomized trials comparing direct oral anticoagulants with vitamin K antagonists

Comparative Effectiveness and Safety of Direct Oral Anticoagulants vs Warfarin among Nursing Home Residents with Atrial Fibrillation: A Retrospective Cohort Study

Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study

Efficacy and Safety of Direct Oral Anticoagulants for Stroke Prevention in Older Patients With Atrial Fibrillation: A Network Meta-Analysis of Randomized Controlled Trials

Effectiveness and safety in non-valvular atrial fibrillation patients switching from warfarin to direct oral anticoagulants in US healthcare claims

Meta-analysis on the comparison of direct oral anticoagulants versus vitamin K antagonists after transcatheter aortic valve implantation in patients with pre-existing atrial fibrillation

Adverse events of direct factor Xa inhibitors: a disproportionality analysis of the FAERS database

Left Atrial Appendage Thrombosis and Oral Anticoagulants: A Meta-Analysis of Risk and Treatment Response

Direct Oral Anticoagulants vs Vitamin K Antagonists in Patients With Antiphospholipid Syndromes: Meta-Analysis of Randomized Trials

Direct oral anticoagulants versus vitamin K antagonists after recent ischemic stroke in patients with atrial fibrillation

Meta-Analysis of the Safety and Efficacy of Direct Oral Anticoagulants for the Treatment of Left Ventricular Thrombus

Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis.